...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >KML001 Enhances Anticancer Activity of Gemcitabine Against Pancreatic Cancer Cells
【24h】

KML001 Enhances Anticancer Activity of Gemcitabine Against Pancreatic Cancer Cells

机译：KML001增强吉西他滨对胰腺癌细胞的抗癌活性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Gemcitabine is a drug commonly used to treat pancreatic cancer but chemoresistance to it is a common clinical issue. KML001 (sodium meta-arsenite) has demonstrated certain antitumor activity. The objective of the study was to evaluate the influence of KML001 on the anticancer activity of gemcitabine against pancreatic cancer cells. Materials and Methods: Cell proliferation, migration, and invasion were assessed, as well as the expression of nuclear factor-kappa B (NF-kappa B) p65, epidermal growth factor receptor (EGFR), matrix metalloproteinase-2 (MMP2), and vascular endothelial growth factor-C (VEGFC) in pancreatic cancer cells. Results: Treatment with a combination of KML001 and gemcitabine resulted in significant inhibition of cell proliferation, migration, and invasion, and significantly reduced EGFR and MMP2 expression compared to gemcitabine treatment-alone. Conclusion: Combination treatment of gemcitabine and KML001 could be an effective chemotherapeutic treatment for pancreatic cancer.
机译：背景/目的：吉西他滨是一种常用于治疗胰腺癌的药物，但对它的化学耐药性是一个常见的临床问题。 KML001（偏亚砷酸钠）已显示出一定的抗肿瘤活性。这项研究的目的是评估KML001对吉西他滨对胰腺癌细胞的抗癌活性的影响。材料和方法：评估细胞的增殖，迁移和侵袭，以及核因子-κB（NF-κB）p65，表皮生长因子受体（EGFR），基质金属蛋白酶-2（MMP2）和胰腺癌细胞中的血管内皮生长因子-C（VEGFC）。结果：与单独吉西他滨治疗相比，用KML001和吉西他滨联合治疗可显着抑制细胞增殖，迁移和侵袭，并显着降低EGFR和MMP2表达。结论：吉西他滨联合KML001治疗胰腺癌可能是一种有效的化疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号